TG Therapeutics Claimed Company
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. read more
HR or Marketing? Claim Your Free Employer Account
Emmanuel Normant — Vice President, Pre-Clinical Sciences at TG Therapeutics
Executive Bio
Emmanuel Normant serves as the Vice President, Pre-Clinical Sciences of TG Therapeutics. Emmanuel Normant and the TG Therapeutics executive team are rated a B by 23 employees.
Executive Team Culture Ratings from TG Therapeutics Employees
TOP
25%
TG Therapeutics' Executive Team scores in the Top 25%
of similar sized companies on Comparably
of similar sized companies on Comparably
TG Therapeutics' Executive Team at a Glance
Based on 26 ratings, TG Therapeutics' employees are satisfied with their Executive Team and give them a “B” or 75/100. On average, Women provided higher ratings for their Executive Team compared to Men.
TG Therapeutics' Executive Team ranks in the Top 20% of other companies in Burlington, NC and Top 25% of other companies on Comparably that also have 201-500 Employees.
×